Literature DB >> 17576831

Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo.

Johan W Mouton1, Nieko Punt, Alexander A Vinks.   

Abstract

Growth-kill dynamics were characterized in vitro, and the parameter estimates were used to simulate bacterial growth and kill in vivo using both mouse and human pharmacokinetics. The parameter estimates obtained in vitro predicted a time above the MIC of between 35 and 38% for a static effect in mice after 24 h of treatment.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17576831      PMCID： PMC2043238          DOI： 10.1128/AAC.01586-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

Review 1.  Animal model pharmacokinetics and pharmacodynamics: a critical review.

Authors:  D Andes; W A Craig
Journal:  Int J Antimicrob Agents       Date:  2002-04       Impact factor: 5.283

Review 2.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.

Authors:  Markus Mueller; Amparo de la Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

3.  Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens.

Authors:  Roland R Regoes; Camilla Wiuff; Renata M Zappala; Kim N Garner; Fernando Baquero; Bruce R Levin
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 4.  Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update.

Authors:  Johan W Mouton; Michael N Dudley; Otto Cars; Hartmut Derendorf; George L Drusano
Journal:  J Antimicrob Chemother       Date:  2005-03-16       Impact factor: 5.790

5.  A pharmacodynamic model for the activity of antibiotics against microorganisms under nonsaturable conditions.

Authors:  J Zhi; C H Nightingale; R Quintiliani
Journal:  J Pharm Sci       Date:  1986-11       Impact factor: 3.534

6.  Kinetics of antimicrobial action.

Authors:  H Mattie
Journal:  Rev Infect Dis       Date:  1981 Jan-Feb

7.  In vitro evaluation of the determinants of bactericidal activity of ampicillin dosing regimens against Escherichia coli.

Authors:  C A White; R D Toothaker; A L Smith; J T Slattery
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

8.  Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers.

Authors:  J W Mouton; A M Horrevorts; P G Mulder; E P Prens; M F Michel
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

9.  Kinetics of antimicrobial activity.

Authors:  B Vogelman; W A Craig
Journal:  J Pediatr       Date:  1986-05       Impact factor: 4.406

10.  Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models.

Authors:  J E Leggett; B Fantin; S Ebert; K Totsuka; B Vogelman; W Calame; H Mattie; W A Craig
Journal:  J Infect Dis       Date:  1989-02       Impact factor: 5.226
View more
  19 in total

1.  Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model.

Authors:  Ken Coleman; Premavathy Levasseur; Anne-Marie Girard; Monica Borgonovi; Christine Miossec; Henri Merdjan; George Drusano; David Shlaes; Wright W Nichols
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

2.  Pharmacodynamics of Cefepime Combined with Tazobactam against Clinically Relevant Enterobacteriaceae in a Neutropenic Mouse Thigh Model.

Authors:  Maria J Melchers; Anita C van Mil; Claudia Lagarde; Jan den Hartigh; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

Review 3.  Pharmacokinetic and pharmacodynamic parameters of antimicrobials: potential for providing dosing regimens that are less vulnerable to resistance.

Authors:  Chiara Adembri; Andrea Novelli
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 4.  What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.

Authors:  Karen Bush; Malcolm G P Page
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-02-04       Impact factor: 2.745

5.  Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization.

Authors:  Elisabet I Nielsen; Otto Cars; Lena E Friberg
Journal:  Antimicrob Agents Chemother       Date:  2011-08-01       Impact factor: 5.191

Review 6.  Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime-Avibactam Combination: A Model-Informed Strategy for its Clinical Development.

Authors:  Sherwin K B Sy; Luning Zhuang; Serubbabel Sy; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2019-05       Impact factor: 6.447

7.  Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis.

Authors:  Timothy J Bensman; Joshua Wang; Jordanna Jayne; Lynn Fukushima; Adupa P Rao; David Z D'Argenio; Paul M Beringer
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

8.  In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.

Authors:  W A Craig; D R Andes
Journal:  Antimicrob Agents Chemother       Date:  2012-12-28       Impact factor: 5.191

9.  Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease.

Authors:  Beatriz E Ferro; Shashikant Srivastava; Devyani Deshpande; Jotam G Pasipanodya; Dick van Soolingen; Johan W Mouton; Jakko van Ingen; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

10.  Exposure to ceftobiprole is associated with microbiological eradication and clinical cure in patients with nosocomial pneumonia.

Authors:  A E Muller; N Punt; J W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2014-02-10       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.